Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- GWRE +14.6%, THO +10.4%, YEXT +8.8%, REVG +7.6%, LITE +7.2%, HPE +6.2%, TTGT +5.9%, HQY +5.3%, GCO +4.3%, APPS +1.3%
Other news:
- SGMT +21.8% (announces Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis met all endpoints)
- CRVS +7.3% (announces new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis)
- TLX +6.7% (receives approval of Illuccix PSMA-PET imaging agent in Portugal)
- ANAB +4.4% (rosnilimab data updated in Phase 2b Trial)
- CANG +3.7% (enters third amendment to share-settled crypto mining assets acquisitions)
- TVTX +3.1% (to present new FILSPARI data)
- WFC +2.7% (Fed removes limits on growth in total assets)
- SNOW +2.5% (INFA expands collaboration with SNOW)
- NG +1.9% (NovaGold Resources and Paulson Advisers complete $1 billion acquisition of Barrick Mining's (B) 50% interest in Donlin Gold)
- ALV +1.8% (raises dividend and authorizes new stock repurchase program; reaffirms FY25 guidance at Capital Markets Day)
- KOS +1.6% (Kosmos Energy and partners sign MOU to extend Ghana production licenses to 2040)
- PSNL +1.4% (presents new clinical results from PREDICT DNA and SCANDARE studies; also new results from the CALLA phase 3 study)
- CPRX +1.2% (CEO bought 70000 shares)
- INFA +1.2% (INFA expands collaboration with SNOW)
- VTS +1.2% (has resolved this pending litigation in North Dakota with Hess)